rituximab + mitoxantrone liposome + cyclophosphamide + vincristine + prednisone

This drug is a **combination chemotherapy regimen** consisting of rituximab (a monoclonal antibody targeting CD20 on B-cells), mitoxantrone liposome (a liposomal formulation of the anthracenedione antineoplastic agent mitoxantrone), cyclophosphamide (an alkylating agent), vincristine (a vinca alkaloid that disrupts microtubule formation), and prednisone (a synthetic glucocorticoid). This multi-agent regimen is designed to achieve synergistic cytotoxic effects in the treatment of hematological malignancies, particularly lymphomas. - **Rituximab** depletes CD20+ B-cells via immune-mediated mechanisms. - **Mitoxantrone liposome** intercalates DNA and inhibits topoisomerase II, causing DNA strand breaks, and its liposomal formulation may enhance tissue targeting and reduce toxicity. - **Cyclophosphamide** cross-links DNA, impairing cell replication. - **Vincristine** inhibits microtubule assembly, disrupting mitosis. - **Prednisone** induces apoptosis in certain cancerous lymphoid cells. While similar combinations have been used for follicular lymphoma and other lymphoproliferative disorders, the specific five-drug combination with liposomal mitoxantrone is not standard and may be under investigation for enhanced efficacy or reduced toxicity profiles.

Other names

cyclophosphamide + methotrexate + vincristine + prednisone + rituximab-The First Affiliated Hospital of Soochow University-non-Hodgkin lymphomaR-CMOPMitoxantrone Liposome-based CMOP±R